Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

SGOV trades at $100.51 with minimal daily movement (+0.04%), reflecting its stable Treasury bond ETF nature. Technical indicators show bearish momentum with oversold RSI readings, while fundamental data remains limited for this short-term Treasury fund. Recent institutional selling by Envestnet Asset Management indicates some professional caution, though the fund continues regular dividend distributions.

The outlook remains stable given SGOV's short-term Treasury focus, though rising bond yields present both opportunity and risk. Investors benefit from monthly dividends but face interest rate sensitivity. Current technical weakness suggests potential near-term pressure despite the fund's defensive characteristics in volatile markets.